ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages

Antiviral Therapy

Volumn 9, Issue 4, 2004, Pages 519-528

  Jorajuria, Sylvie ^a   Dereuddre Bosquet, Nathalie ^b   Becher, François ^c   Martin, Solenne ^c   Porcheray, Fabrice ^a   Garrigues, Alexia ^c   Mabondzo, Aloise ^c   Benech, Henri ^c   Grassi, Jacques ^c   Orlowski, Stéphane ^c   Dormont, Dominique ^a   Clayette, Pascal ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ANTIRETROVIRUS AGENT; GLYCOPROTEIN P; INDINAVIR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; PROBENECID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALSPODAR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG TRANSPORT; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE; MACROPHAGE; MASS SPECTROMETRY; MEMBRANE VESICLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELLS, CULTURED; CYCLOSPORINS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROBENECID; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; ZIDOVUDINE;

EID: 4344667716     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, Lauenroth-Mai E, Moll A, Schranz D, Moecklinghoff C & Arasteh K. Predictors of treatment failure during highly active antiretroviral therapy (racing trial). European Journal of Medical Research 2002; 7:341-346.
2. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW & Belanger A. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metabolism & Disposition: the Biological Fate of Chemicals 2000; 28:497-502.
3. King CD, Rios GR, Assouline JA & Tephly TR. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Archives of Biochemistry & Biophysics 1999; 365:156-162.
4. Veal GJ & Back DJ. Metabolism of zidovudine. General Pharmacology 1995; 26:1469-1475.
5. Sawchuk RJ & Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Advanced Drug Delivery Reviews 1999; 39:5-31.
6. Gupta S & Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. Journal of Clinical Immunology 1993; 13:289-301.
7. Laupeze B, Amiot L, Payen L, Drenou B, Grosset JM, Lehne G, Fauchet R & Fardel O. Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sciences 2001; 68:1323-1331.
8. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR & Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proceedings of the National Academy of Sciences, USA 1989; 86:695-698.
9. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC & Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proceedings of the National Academy of Sciences, USA 1999; 96:3900-3905.
10. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J & Borst P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proceedings of the National Academy of Sciences, USA 2000; 97:7476-7481.
11. Lai L & Tan TM. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochemical Journal 2002; 361:497-503.
12. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A & Fridland A. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Medicine 1999; 5:1048-1051.
13. Signoretti C, Romagnoli G, Turriziani O, Antonelli G, Dianzani F & Cianfriglia M. Induction of the multidrug-transporter P-glycoprotein by 3′-azido-3′-deoxythymidine (AZT) treatment in tumor cell lines. Journal of Experimental Clinical Cancer Research 1997; 16:29-32.
14. Lee CG & Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. Journal of Clinical Investigation 1998; 101:287-288.
15. Washington CB, Duran GE, Man MC, Sikic BI & Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1998; 19:203-209.
16. Srinivas RV, Middlemas D, Flynn P & Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrobial Agents & Chemotherapy 1998; 42:3157-3162.
17. Olson DP, Scadden DT, D'Aquila RT & De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 2002; 16:1743-1747.
18. +-dependent high-affinity glutamate transport in macrophages. Journa of Immunology 2000; 164:5430-5438.
19. Benveniste O, Martin M, Villinger F & Dormont D. Techniques for quantification of cytokine mRNAs. Cytokines, Cellular & Molecular Therapy 1998; 4:207-214.
20. Jorajuria S, Clayette P, Dereuddre-Bosquet N, Benlhassan-Chahour K, Thiebot H, Vaslin B, Le Grand R & Dormont D. The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS. AIDS Research & Human Retroviruses 2003; 19:307-311.
21. Duval X, Clayette P, Dereuddre-Bosquet N, Fretier P, Martin M, Salmon-Ceron D, Gras G, Vilde JL & Dormont D. Dapsone and HIV-1 replication in primary cultures of lymphocytes and monocyte-derived macrophages. AIDS 1997; 11:943-944.
22. Kornhauser DM, Petty BG, Hendrix CW, Woods AS, Nerhood LJ, Bartlett JG & Lietman PS. Probenecid and zidovudine metabolism. Lancet 1989; 2:473-475.
23. Becher F, Schlemmer D, Pruvost A, Nevers MC, Goujard C, Jorajuria S, Guerreiro C, Brossette T, Lebeau L, Creminon C, Grassi J & Benech H. Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Analytical Chemistry 2002; 74:4220-4227.
24. Devine SE, Ling V & Melera PW. Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proceedings of the National Academy of Sciences, USA 1992; 89:4564-4568.
25. Garrigos M, Mir LM & Orlowski S. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase-further experimental evidence for a multisite model. European Journal of Biochemistry 1997; 244:664-673.
26. Kantharidis P, El-Osta S, Silva M, Lee G, Hu XF & Zalcberg J. Regulation of MDR1 gene expression: emerging concepts. Drug Resistance Updates 2000; 3:99-108.
27. Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH & Schuetz JD. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002; 4:E14.
28. Bohme M, Jedlitschky G, Leier I, Buchler M & Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Advances in Enzyme Regulation 1994; 34:371-380.
29. Paul S, Breuninger LM & Kruh GD. ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Biochemistry 1996; 35:14003-14011.
30. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T & Endou H. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. European Journal of Pharmacology 2001; 419:113-120.
31. Perloff MD, von Moltke LL & Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. Journal of Clinical Pharmacology 2002; 42:1269-1274.
32. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R & Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001; 15:675-681.
33. van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG & Breimer DD. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 2001; 15:483-491.
34. Owen A, Chandler B, Ford J, Khoo S & Back D. Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells. Journal of Infectious Diseases 2003; 187:874-875.
35. Hodges VM, Molloy GY & Wickramasinghe SN. Demonstration of mRNA for five species of cytochrome P450 in human bone marrow, bone marrow-derived macrophages and human haemopoietic cell lines. British Journal of Haematology 2000; 108:151-156.
36. Hochman JH, Chiba M, Yamazaki M, Tang C & Lin JH. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. Journal of Pharmacology & Experimental Therapeutics 2001; 298:323-330.
37. Glynn SL & Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. Journal of Pharmaceutical Sciences 1998; 87:306-310.
38. Gollapudi S, Kim CH, Tran BN, Sangha S & Gupta S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemotherapy & Pharmacology 1997; 40:150-158.
39. Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH & Borst P. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Molecular Pharmacology 2002; 62:1321-1331.
40. van Aubel RA, Smeets PH, Peters JG, Bindels RJ & Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. Journal of the American Society of Nephrology 2002; 13:595-603.
41. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T & Endou H. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. Journal of Pharmacology & Experimental Therapeutics 2002; 300:918-924.
42. Strazielle N, Belin MF & Ghersi-Egea JF. Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters. AIDS 2003; 17:1473-1485.
43. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S & Baba M. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Molecular Pharmacology 2003; 63:65-72.
44. Keim D, Hailat N, Melhem R, Zhu XX, Lascu I, Veron M, Strahler J & Hanash SM. Proliferation-related expression of p19/nm23 nucleoside diphosphate kinase. Journal of Clinical Investigation 1992; 89:919-924.
45. Hu XF, Slater A, Wall DM, Parkin JD, Kantharidis P & Zalcberg JR. Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clinical Cancer Research 1996; 2:713-720.